Compare LTC Properties Inc (LTC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Repligen Corporation Common Stock — how do they compare? LTC Properties Inc trades at $43.09 (market cap $2.31B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 4.8× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.31% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 89 Days and Repligen Corporation Common Stock for 0 Days on average.
| LTC | RGEN | |
|---|---|---|
Market Cap | $2.31B | $11.14B |
Volume | 323,404 | 1,259,263 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $194.57 |
52-Week Low | $34.04 | $102.87 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $3.05B | $11.02B |
Dividend Yield | 5.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $43.20, up 0.35% with a bullish technical signal and strong fundamental metrics including 38.93% net income margin and 12.11% ROE. Recent acquisitions totaling $360 million accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Revenue growth continues with 2025 revenue reaching $263 million, though profit margins have moderated from historical highs.
The outlook remains positive with analyst consensus target of $49.67 representing 15% upside potential. Key risks include rising interest rates impacting REIT valuations and execution challenges in portfolio transformation. The stock offers balanced risk-reward with income generation and growth potential from strategic acquisitions in the seniors housing sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
